Bracco Diagnostics Unveils Updated HeartSee Software for Cardiac PET Imaging
New updates for the cardiac PET-based HeartSee v4.0 software include an emphasis on the evaluation of subendocardial ischemia and border zones.
In order to facilitate enhanced assessment of myocardial blood flow (MBF) with cardiac positron emission tomography (PET), Bracco Diagnostics has released updated HeartSee v4.0 software.
The company said key benefits of the HeartSee v4.0 software include:
• measurement of subendocardial ischemia;
• assessment of relative stress flow, which allows indirect evaluation of subendocardial border zones in areas with mild reduction of coronary flow capacity (CFC); and
• additional data on ejection fraction.
Here one can see single views of positron emission tomography (PET) scans revealing different patterns of severely reduced coronary flow capacity (CFC). New updates for the HeartSee software for cardiac PET include a relative stress flow feature, which facilitates assessment of subendocardial border zones in areas with mildly reduced CFC. (Images courtesy of the Journal of Nuclear Medicine.)
"These improvements underscore our dedication to supporting physicians in making informed decisions that improve patient outcomes. We believe the new features of HeartSee will set a new standard in cardiac care, helping to detect and treat coronary artery disease more effectively and efficiently than ever before,” noted Derek Steptoe, the senior manager of nuclear cardiology at Bracco Diagnostics.
In addition to the software’s compatibility with Windows 10 and 11 operating systems at hospitals and other health-care facilities, Bracco Diagnostics said it provides dedicated field support and training for the HeartSee v4.0 software.
Recent Videos
Related Content
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025Article
For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025Podcast
In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Article
Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025Article
The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
